Clinical Trial Update: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) [Phase 2]

View source ↗

Summary

A Phase 2 trial is enrolling to evaluate Durvalumab in combination with carboplatin and etoposide for pulmonary large-cell neuroendocrine carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Large-cell Neuroendocrine Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Durvalumab (durvalumab)
• Etoposide (Etoposide)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Pulmonary Large-cell Neuroendocrine Carcinoma | Phase 2 | Status: RECRUITING